Clinical trials: Hypersensitivity
Conjunctivitis, Allergic
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a…
- Trial name
- NCT01289431
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Bausch & Lomb Incorporated
Atopic Dermatitis
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Heads Up (NCT03738397)
- Testing
- Upadacitinib, Dupilumab
- Where
- 159 sites in United States, Australia and 21 more
- Volunteers
- 673 people
- Sponsor
- AbbVie
Dermatitis, Atopic
A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo
This study is a randomised, double-blind, placebo-controlled study to assess the efficacy of GW870086X cream formulation in subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT01299610
- Testing
- GW870086 2.0%, GW870086 0.2%, FP 0.05%
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Chronic Migraine, Olfactory Acuity
Smell Sensitivity in Chronic Migraine: A Case-Control Study
Olfactory impairment is a common symptom of neurologic disorders and may be related to dopaminergic dysfunction. Studies show that patients with migraine show increased sensitivity to light and sound.
- Trial name
- NCT01687088
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
Asthma
Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch…
- Trial name
- QVM149 (NCT03108027)
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Pharmacokinetics, Epinephrine
Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation, versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy adults.
- Conditions
- Pharmacokinetics, Epinephrine, Albuterol, Asthma
- Trial name
- NCT04207840
- Testing
- Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma
The pharmacokinetic (PK) profile of tralokinumab (CAT-354) will be studied in adolescent subjects with asthma.
- Trial name
- NCT01592396
- Testing
- Tralokinumab 300 mg
- Where
- 3 sites in Poland
- Volunteers
- 30 people
- Sponsor
- MedImmune LLC
Penicillin Allergy
Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal in ICU Setting
Currently it is estimated that at least 25 million people in the United States are labeled as penicillin allergic although less than 1.5 million of these are truly allergic.
- Trial name
- NCT03702283
- Testing
- Penicillin Allergic Risk Stratification Best Practice Alert
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Atopic Dermatitis
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).
- Trial name
- NCT03745651
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 66 sites in United States, Bulgaria and 5 more
- Volunteers
- 618 people
- Sponsor
- Incyte Corporation
Perennial Allergic Rhinitis
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
This study was conducted to see if mometasone nasal spray is efficaceous for the treatment of perennial allergic rhinitis. Patients will be randomized to active mometasone, placebo mometasone, active fluticasone, or placebo…
- Trial name
- NCT00783224
- Testing
- Mometasone, Fluticasone
- Volunteers
- 351 people
- Sponsor
- Organon and Co
Asthma Chronic
Azithromycin Treatment for the Airway Microbiome in Asthma
The purpose of this study to determine whether the bacteria inside the lungs of people with asthma can be modified (changed) if they are given an antibiotic and if this change is associated with an improvement in asthma symptoms.
- Trial name
- NCT03736629
- Testing
- Azithromycin
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Allergic Rhinitis, Conjunctivitis
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
- Trial name
- NCT04709575
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 353 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Spontaneous Urticaria
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
The purpose of this study was to establish the efficacy, safety, and tolerability of Remibrutinib 25 mg b.i.d. in adult patients suffering from chronic spontaneous urticaria (CSU) inadequately controlled by second generation…
- Trial name
- REMIX-2 (NCT05032157)
- Testing
- LOU064 (blinded), LOU064 (open-label)
- Where
- 122 sites in United States, Austria and 16 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Idiopathic Urticaria
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of omalizumab administered subcutaneously as an add-on therapy for the treatment…
- Trial name
- NCT01264939
- Testing
- Omalizumab, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
- Where
- 73 sites in United States, Australia and 6 more
- Volunteers
- 336 people
- Sponsor
- Genentech, Inc.
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Dermatitis, Atopic
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- GENESIS (NCT04791319)
- Testing
- Bermekimab, Dupilumab
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 199 people
- Sponsor
- Janssen Research & Development, LLC
Dermatitis, Atopic
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)
- Trial name
- NCT01602341
- Testing
- AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, AN2728 Topical Ointment, 2% BID
- Where
- 17 sites in United States, Australia
- Volunteers
- 86 people
- Sponsor
- Pfizer
Atopic Dermatitis, Plaque Psoriasis
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
- Trial name
- EMPORIA (NCT04664153)
- Testing
- PF-07038124 ointment, Vehicle ointment
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 104 people
- Sponsor
- Pfizer
Hereditary Angioedema, Angioneurotic Edema
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening.
- Conditions
- Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders
- Trial name
- NCT00262301
- Testing
- recombinant human C1 inhibitor
- Where
- 2 sites in Netherlands, Romania
- Volunteers
- 75 people
- Sponsor
- Pharming Technologies B.V.
Asthma
Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.
- Trial name
- NCT00410280
- Testing
- IMA-638 is a biologic
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.